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Abstract 
Aims:  Opioid use disorder (OUD) is associated with significant morbidity and mortality, 
and opioid agonist treatment (OAT) with methadone or buprenorphine represents the 
most efficacious treatment.  However, data suggest that chronic administration of opioids 
may be associated with significant weight gain, possibly by altering an organism’s 
perception of and preference for sweet foods.  The primary aim of this laboratory study 
was to rigorously examine sucrose subjective response among adults receiving OAT and 
a comparison sample without OUD.  As secondary outcomes, we also sought to compare 
the groups on additional baseline characteristics that may influence subjective sucrose 
response and weight gain during treatment. 
 
Methods:  Participants were 40 adults receiving treatment for OUD (OUD+) and a 
comparison sample of 40 adults without OUD (OUD-).  All participants completed an 
initial screening visit that included questionnaires on eating behaviors, diet and nutrition, 
recent substance use, and measurement of body mass index.  Eligible participants 
completed two, same-day outpatient laboratory sessions during which they sampled six 
experimenter-administered concentrations of sucrose solution (0, 0.1, 0.25, 0.5, 0.75, and 
1.0M in distilled water) each three times under double-blind counterbalanced conditions.  
Following each exposure, participants rated the pleasantness and intensity of each sample 
using 100-point visual analog scales. 
 
Results:  OUD+ participants rated sucrose solutions as less pleasant than OUD- 
participants (p<0.001).  However, this effect was limited to the three lowest sucrose 
concentrations (0, 0.1, 0.25M), and at higher concentrations there were no group 
differences.  There were no between-group differences on ratings of intensity (p=0.35).  
Given these baseline group differences in placebo (0M) responding, sucrose response was 
also examined in terms of change from baseline.  In this analysis, there was a significant 
group effect, with a higher magnitude of change in pleasantness ratings and a lower 
magnitude of change in intensity ratings from 0M in OUD+ vs. OUD- participants 
(p’s<0.05).  With regard to baseline characteristics that may influence sucrose response 
and eating behavior more generally, the OUD+ group had a higher prevalence of obesity, 
food insecurity, unhealthy eating behaviors, high sugar consumption, and nutrition 
knowledge deficits compared to the OUD- group (p’s<0.05).  
 
Conclusion:  Data from preclinical and clinical research have suggested that opioid 
agonist medications may enhance subjective response to sweet flavors.  In the present 
study, OUD+ participants exhibited a higher magnitude of change in pleasantness ratings 
from placebo compared to OUD- participants.  However, this effect was largely driven by 
pronounced group differences in perceived pleasantness of essentially unsweet solutions. 
On the outcome of sucrose intensity, findings were more mixed with no consistent 
differences between OUD+ and OUD- participants.  In contrast, group differences were 
far more pronounced in participants’ daily eating behaviors and nutrition knowledge, 
with OUD+ participants presenting with a consistently more severe profile.  These data 
highlight the significant risk factors experienced by OUD+ individuals that extend 
beyond drug-related risks and may inform future scientific and clinical efforts to improve 
health outcomes in this vulnerable population.
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1. Introduction 
The current United States opioid epidemic represents the most devastating public 
health crisis of our time, with nearly 12 million Americans reporting opioid misuse in 
2016 (SAMHSA, 2017).  Opioid use disorder (OUD) is associated with a multitude of 
consequences including infectious disease, overdose and premature death, as well as 
significant economic costs estimated at over $78 billion annually (Birnbaum et al., 2011; 
Clausen, Waal, Thoresen, & Gossop, 2009; Gomes, Tadrous, Mamdani, Paterson, & 
Juurlink, 2018; Hser, Hoffman, Grella, & Anglin, 2001; Scholl, Seth, Kariisa, Wilson, & 
Baldwin, 2019).   
Opioid agonist treatment (OAT) with methadone or buprenorphine is the most 
efficacious treatment for OUD (Mattick, Breen, Kimber, & Davoli, 2014).  Methadone is 
a µ-opioid full agonist; whereas buprenorphine is a µ-opioid partial agonist that has a 
distinct pharmacological profile characterized by a ceiling effect on its agonist activity, a 
long plasma half-life, and slow dissociation from the µ-opioid receptor (Johnson, 2003; 
Sigmon, Wong, Chausmer, Liebson, & Bigelow, 2004; Walsh, 2003).  Maintenance 
treatment with methadone or buprenorphine has been consistently shown to reduce illicit 
opioid use, withdrawal symptoms, risky drug use behaviors, contraction of infectious 
disease, overdoses, criminal activity and premature death (Mattick, Breen, Kimber, & 
Davoli, 2009; Mattick et al., 2014; National Academies of Sciences, Engineering, and 
Medicine, 2019; Volkow, Jones, Einstein, & Wargo, 2019).  
 Despite its undisputed efficacy for reducing morbidity and mortality associated 
with OUD, OAT may also be associated with several adverse health effects.  One that we 
have become especially interested in is the possibility that chronic administration of 
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opioids may be associated with significant weight gain.   In a recent retrospective chart 
review we examined body mass index (BMI) and weight changes among 96 patients 
receiving methadone maintenance treatment at two timepoints: at treatment intake and 
again approximately two years later (Fenn, Laurent, & Sigmon, 2015).  We observed a 
significant increase in BMI following entry into methadone treatment (p<0.001), with 
mean BMIs increasing from 27.2±6.8 to 30.1±7.7 kg/m2 at Times 1 and 2, respectively.  
This translated to an increase from 177.6 to 195.4 pounds, representing a 10% (17.8-
pound) increase in body weight.  These data are consistent with several prior studies that 
have found significant weight gains during OAT, particularly during treatment with 
methadone.  A recent study of 114 methadone-maintained patients in Israel, for example, 
found significant weight gain early in treatment, with mean BMIs increasing 8% within 
the first year of treatment (Peles, Schreiber, Sason, & Adelson, 2016).  Among 55 
methadone patients in Iran, a similar increase in BMI was detected within only the first 
two months of treatment, with mean BMIs increasing by 7% and the percentage of 
patients meeting criteria for obesity increasing from 3.6% to 7.2% during the eight weeks 
following treatment entry (Montazerifar, Karajibani, & Lashkaripour, 2012).  In a recent 
study of 74 methadone patients in the U.S., 42% of patients met criteria for overweight, 
obese, or morbidly obese at treatment entry; this increased to 76%, 82%, and 88% at one, 
two, and three years post-intake, respectively (Sweeney et al., 2018).  A single recent 
study found similar weight gains during buprenorphine treatment, with 107 adult 
inpatients in Turkey experiencing a mean body weight increase of 8% by the fourth 
month of buprenorphine maintenance (p<0.001; Baykara & Alban, 2019).  Overall, of the 
13 published studies that have evaluated changes in weight during OAT, 92% have 
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reported statistically significant increases following OAT entry (Table 1).  These 
potential shifts of patients into overweight or obese categories may place patients at 
heightened risk of developing cardiovascular disease, stroke, diabetes, cancer, and 
premature death (Fenn et al., 2015; Mysels & Sullivan, 2010; Schlienz, Huhn, Speed, 
Sweeney, & Antoine, 2018).   
One possible explanation for these weight gains during treatment is that they may 
simply be a function of undernourished illicit drug abusers moving toward a healthier 
weight as they become stabilized in opioid treatment (Gronbladh & Ohlund, 2011; 
Okruhlica & Slezakova, 2008).  However, the data thus far do not strongly support this 
explanation.  Across the studies that have reported BMI changes during treatment, 
patients generally moved from the normal (rather than underweight) category at intake to 
an overweight or obese BMI following enrollment into OAT.  In our recent investigation 
in the methadone clinic, for example, patients were generally already in the overweight 
category at treatment intake (BMIs 25.0-29.9 kg/m2) and transitioned into the obese 
category (BMI >30.0 kg/m2) by the second assessment timepoint.   
1.1 Potential opioid effects on sweet subjective response 
Preclinical studies 
Another possibility is that administration of opioid agonists may alter, and in 
particular enhance, an organism’s perception of and preference for sweet foods (Mysels 
& Sullivan, 2010).  The most experimentally rigorous studies on this have been 
conducted in non-human animals and have generally shown that experimenter-
administered opioid agonists are associated with increased ingestion of sweetened 
solutions or food (Castro & Berridge, 2017; Comer, Evans, Pudiak, & Foltin, 2002; 
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Daniels, Pratt, Zhou, & Leri, 2018; Gagin, Cohen, & Shavit, 1996; Pecina & Berridge, 
2005; Zhang & Kelley, 2002).  In a recent study examining the effect of methadone 
administration on consumption of rat chow and a liquid high fructose corn syrup solution, 
for example, methadone concurrently decreased intake from chow and increased intake of 
the sweetened solution (Daniels et al., 2018).  In another, microinjection of a µ-opioid 
agonist in rats potentiated measures of liking of a sucrose solution by 200-300% and 
increased sweet food consumption (Castro & Berridge, 2017).     
Providing further evidence of a potential pharmacological effect of opioid 
agonists on individuals’ subjective response to sweet taste, administration of opioid 
antagonists (e.g., naltrexone, naloxone) has been shown to reduce preference for and 
intake of sweetened solutions and foods (Kirkham, 1990; Levine, Weldon, Grace, Cleary, 
& Billington, 1995; Rockwood & Reid, 1982; Yirmiya, Lieblich, & Liebeskind, 1988).  
For example, naltrexone administration has been associated with reduced preference for 
and intake of saccharin solution in mice (Yirmiya et al., 1988).  In a later study, naloxone 
reduced intake of sweetened vs. normal chow in both food-deprived and 50% satiated rats 
(Levine et al., 1995).   
Clinical studies 
While the pre-clinical evidence with opioid agonists and antagonists has generally 
supported a potential pharmacological mechanism underlying the influence of opioids on 
sweet subjective response, the clinical data on this topic have been more mixed.  Those 
studies have generally utilized an experimental procedure called a sweet taste test, 
wherein individuals sample a variety of sucrose solutions under double-blind conditions 
and then rate the pleasantness (i.e., self-reported liking) and intensity (i.e., self-reported 
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sweetness) of each concentration.  Two such studies have been conducted evaluating 
sweet taste response among individuals maintained on methadone or buprenorphine for 
treatment of OUD (Bogucka-Bonikowska et al., 2002; Green et al., 2013).  In the first, 28 
male methadone-maintained patients and a comparison sample of 32 male adults without 
a history of OUD sampled three solutions that varied in sucrose concentration (ranging 
from 0M to 0.88M) as well as a negative control solution (i.e., 0M sucrose) (Bogucka-
Bonikowska et al., 2002).  A small amount (10mL) of each solution was administered 
once on the tongue via a syringe in counterbalanced order across subjects.  Following 
each exposure, participants rated the solution’s pleasantness (-50 to +50) and intensity (0 
to 100) on a 100mm visual analog scale (VAS).  There were no significant between-
group differences in ratings of sweet pleasantness or intensity for any sucrose solution.  
However, in the dietary information collected from both groups at study screening, the 
methadone-maintained group did report adding significantly more sugar to beverages 
than controls (2.3 vs. 1.3 spoonfuls per cup, respectively).   
In the second study, 14 patients receiving OAT (7 methadone, 7 buprenorphine) 
and a comparison sample of 65 adults without a history of illicit drug use sampled each of 
10 sucrose concentrations ranging from 1.0 millimolar (mM) to 1.0 molar (M) sucrose 
per liter (L) of distilled water (Green et al., 2013).  Each solution was administered five 
times on the tip of the tongue via cotton swab under double-blind counterbalanced 
conditions to determine sweet taste threshold, which was operationalized as the 
concentration at which the participant could detect the solution in 2.5 of 5 (50%) 
presentations.  For the measures of sweet pleasantness and intensity, participants swished 
5mL of the highest sucrose solution (1.0M) in their mouth.  They then rated the solution’s 
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taste pleasantness (-50 to +50) and intensity (0 to 100).  Sucrose threshold recognition 
ratings were significantly greater in the OMT vs. comparison participants.  That is, larger 
concentrations of sucrose (equal to about 3-4 teaspoons of sugar per mug) were needed 
for the OMT group to detect sweet taste.  Among OMT participants, methadone dose was 
significantly and positively correlated with sucrose threshold recognition.  Ratings of 
sweet pleasantness and intensity for the largest sucrose concentration (1.0M) were 
significantly (approximately three- and two-fold, respectively) greater in the opioid-
maintained vs. comparison group.     
Two additional clinical studies examined the effects of both opioid agonists and 
antagonists on sweet subjective response (Eikemo et al., 2016; Langleben, Busch, 
O’Brien, & Elman, 2012).  In the first, 15 recently-detoxified heroin users sampled 5 
sucrose concentrations (ranging from 0.05 to 0.83M) three times each and provided 
ratings of sweet taste pleasantness, intensity, and wanting (i.e., extent that they want to 
have more of the sample) before and after an injection of extended-release naltrexone 
(Langleben et al., 2012).  Compared to the pre-naltrexone baseline, ratings for sweet taste 
pleasantness were significantly reduced one week after the naltrexone injection.  The 
second study was a randomized, double-blind, placebo-controlled study comparing acute 
morphine vs. naltrexone administration on sweet taste ratings and intensity in 49 male 
adults without a history of OUD (Eikemo et al., 2016).  Participants sampled five sucrose 
concentrations (ranging 0.05 to 0.65M) three times each and rated sweet pleasantness and 
intensity.  These sucrose exposures occurred following acute administration of morphine 
(10 mg), naltrexone (50 mg), or placebo.  Participants’ ratings of sweet pleasantness in 
response to the highest sucrose concentration (0.65M) were significantly greater 
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following morphine administration vs. naltrexone and placebo.  In contrast, there were no 
effects of drug administration on participant ratings of sweet intensity.  Contrary to 
hypotheses, however, ratings of sweet pleasantness following the two lowest sucrose 
concentrations (0.05 and 0.10M) were actually higher during the naltrexone vs. morphine 
and placebo conditions, suggesting the association between opioids and sweet subjective 
response may vary as a function of sucrose concentration and highlighting the importance 
of evaluating multiple concentrations.   
1.2 Nutrition and eating behavior 
These data suggesting that administration of opioid agonist medications may 
increase individuals’ liking of and preference for sweetened foods is generally consistent 
with the larger nutrition literature reporting that opioid-maintained individuals often 
report elevated craving for and consumption of refined carbohydrates, particularly in the 
form of the added sugars in desserts and other sweetened foods and beverages (Alves et 
al., 2011; Gambera & Clarke, 1976; Li., Ryan, & Neale, 2016; Nolan & Scagnelli, 2007; 
Peles et al., 2016; Szpanowka-Wohn, Dłuzniewska, Groszek, & LangMłynarska, 2000; 
Tomedi, Bogen, Hanusa, Wisner, & Bodnar, 2012; Zador, Wall, & Webster, 1996).  In 
one study of methadone-maintained females in Australia, for example, patients consumed 
significantly more sugar per day compared to a nationally representative sample of 
women (122g vs. 101g, respectively) (Zador et al., 1996).  The contribution of sugar to 
daily total energy intake was higher in the methadone-maintained vs. comparison group 
(31% vs. 20%, respectively).  Additional studies have found higher levels of sugar 
consumption and craving among individuals with vs. without OUD (Morabia et al., 1989; 
Nolan & Scagnelli, 2007; Tomedi et al., 2012).    
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1.3 Summary 
Taken together, data suggest that opioid agonists may increase the liking and 
consumption of sweetened foods, which may play a role in the significant weight gain 
and place patients at risk for overweight, obesity and their related adverse health 
consequences.  This potential interaction is also important and timely given the 
increasing numbers of individuals developing OUD and entering methadone or 
buprenorphine maintenance treatment (Alderks, 2017; Wen, Hockenberry, & Pollack, 
2018).   
1.4 Current study 
The prior studies evaluating the effects of opioids on sweet subjective response in 
individuals with OUD have had several limitations.  Nearly all focused on methadone, 
rather than the partial agonist buprenorphine which is being increasingly used for 
treatment of OUD (Volkow et al., 2019; Wen et al., 2018).  Most of the study samples 
were also exclusively (Bogucka-Bonikowska et al., 2002; Eikemo et al., 2016) or 
predominantly (Langleben et al., 2012) male, limiting the generality of their findings to 
females with OUD.  This may be important as gender was the strongest predictor of BMI 
changes in our prior study with methadone-maintained patients (Fenn et al., 2015), with 
significantly greater BMI increases in females than males that translated to a 28-pound 
(17.5%) increase in females vs. a 12-pound (6.4%) increase in males.  Finally, the two 
prior studies that have examined sweet intensity and pleasantness in opioid-maintained 
patients did so using a limited number of sucrose concentrations (4 and 1, respectively; 
Bogucka-Bonikowska et al., 2002; Green et al., 2013).   
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In the present laboratory study, we sought to improve upon these prior limitations 
by evaluating sucrose subjective response among adults receiving OAT and a comparison 
sample of adults without OUD using a larger sample than was used in previous studies.  
We aimed to enroll generally comparable proportions of individuals receiving methadone 
or buprenorphine treatment for OUD, as well as comparable numbers of males and 
females.  Additionally, we examined a wider range of sucrose concentrations than in 
prior studies and also took care to control for timing of the sweet test procedure 
administration in relation to OAT participants’ opioid dose timing (described more 
below).   
Primary aim 
Our primary aim in this study was to compare sucrose subjective response among 
adults receiving OAT for OUD (OUD+) and a comparison sample of adults without 
opioid or other drug use disorders (OUD-).  Under double-blind, counterbalanced 
conditions, participants sampled six concentrations of sucrose (0, 0.1, 0.25, 0.5, 0.75, and 
1.0M in distilled water) each three times and rated the pleasantness and intensity of each 
sample.  We hypothesized that, relative to the OUD- group, OUD+ participants would 
have a steeper dose effect curve associated with pleasantness and intensity ratings across 
the six sucrose concentrations, resulting in higher ratings at the highest concentration and 
greater total area under the sucrose dose curve (AUC).  To permit a rigorous evaluation 
of subjective sucrose response at less risk of confounding by opioid dose timing, 
participants in both groups completed the sweet taste test sessions twice.  Specifically, 
participants sampled and rated the six sucrose concentrations described above during two 
same-day experimental sessions, scheduled three hours apart (corresponding to 
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approximate trough/peak medication levels for the OUD+ group).   
Secondary aims 
We also sought to examine additional baseline characteristics which may 
influence eating behavior and weight gain among patients with OUD (Gambera & 
Clarke, 1976; Nabipour, Said, & Habil, 2014; Neale, Nettleton, Pickering, & Fischer, 
2012;  Nolan & Scagnelli, 2007).  As individuals with OUD and other substance use 
disorders (SUDs) are particularly vulnerable to food insecurity and food insufficiency 
(Himmelgreen et al., 1998; McLinden et al., 2018; Sigmon, 2016) and food insecurity is 
associated with overeating, weight gain and obesity in the general population 
(Dhurandhar, 2016; Kaiser, Dionne, & Carr, 2019; Rasmusson, Lydecker, Coffino, 
White, & Grilo, 2019), we examined past-year food security.  We also evaluated 
measures related to eating behaviors, dietary intake and nutrition knowledge, as research 
has suggested that these may be strongly associated with obesity and may also influence 
development of SUD and treatment outcomes (Jeynes & Gibson, 2017; Richardson & 
Wiest, 2015; Schroeder & Higgins, 2017).  Overall, as these secondary outcomes were 
more exploratory in nature, we did not propose directional hypotheses; however, they did 
provide a unique opportunity to better understand how eating and nutrition related 
behaviors and knowledge that are important in the general population may differ among 
individuals with OUD.  
2. Methods 
2.1 Participants 
 Participants were 80 adults with (OUD+, n=40) and without (OUD-, n=40) OUD.  
The primary referral source was IRB-approved flyers posted in the community as well as 
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local opioid treatment programs.  Additional recruitment and referral sources included 
referrals from community providers, public service announcements, and Facebook 
advertisements.  To be eligible, OUD+ participants had to be >18 years old, currently 
receiving methadone or buprenorphine treatment for OUD and on a stable dose for >3 
months.  OUD- participants had to be >18 years old, generally healthy and without 
current use of opioids or other illicit drugs.  For both groups, individuals with a 
significant psychiatric or medical illness that may interfere with consent or participation 
were excluded, as were those who were pregnant or nursing.  Individuals currently using 
psychoactive medications including antidepressants in the monoamine oxidase inhibitor 
and tricyclic classes, antipsychotics (e.g., haloperidol, pimozide, zotepine), mood 
stabilizers (e.g., valproate or lithium), d-amphetamine and other stimulant medications, 
and benzodiazepines were excluded, as these medications may impact taste function and 
weight (Schlienz et al., 2018; Weafer, Lyon, Hedeker, & de Wit, 2017).  Urine specimens 
were collected at the intake screening visit (described below) and participants testing 
positive for any drug other than prescribed allowable medication, cannabis, or cotinine 
were also excluded.  Consistent with prior studies on this topic (Eikemo et al., 2016; 
Green et al., 2013), we also excluded individuals with high levels of caffeine, alcohol and 
cigarette use as high doses of those drugs may modulate taste perception and sensitivity 
to the reinforcing effects of sucrose (Choo, Picket, & Dando, 2017; Kampov-Polevoy, 
Garbutt, & Janowsky, 1997; Pomerleau, Garcia, Drewnowski, & Pomerleau, 1991).  
More specifically, those who reported caffeine intake exceeding 6 cups of coffee or 
600mg caffeine per day, were physically dependent on alcohol, or smoked >20 cigarettes 
per day were ineligible for the study.  Individuals meeting the above criteria and 
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interested in the study were eligible to participate.  Participants provided written 
informed consent prior to participating.   
2.2 Screening Session 
 Participants completed an initial eligibility screening assessment that consisted of 
a Timeline Followback of past-month caffeine intake, opioid use, tobacco use, alcohol 
use, and prescription and over-the-counter medication use (Sobell & Sobell, 1992), a 
brief medical history and measurement of height, weight and BMI.  Participants also 
completed the Eating Behavior Questionnaire (Nolan & Scagnelli, 2007), the US Adult 
Food Security Survey (Economic Research Service, USDA, 2012), NHANES Food 
Frequency Questionnaire (CDC, 2017), Power of Food Scales (Lowe et al., 2009), and 
the Nutrition Knowledge Questionnaire (Moynihan et al., 2007; Peles et al., 2016).  
These instruments were administered either in pencil-and-paper format or via a secure, 
IRB-approved online platform (Qualtrics, Provo, UT).  Participants provided a urine 
specimen analyzed on-site for opioids (i.e., methadone, buprenorphine, oxycodone, 
hydrocodone, hydromorphone, heroin, fentanyl, morphine) and other drugs (i.e., cocaine, 
amphetamines, benzodiazepines, marijuana, cotinine) via enzyme multiplied 
immunoassay (EMIT; Microgenics, Fremont, CA).  Finally, participants provided a 
breath sample to assess for recent alcohol use (ALCO-SENSOR III, Intoximeters, Inc., 
St. Louis, MO).  Participants received $30 for completing this initial screening session.  
2.3 Measures  
Screening Session Measures 
Body Mass Index.  Participants’ weight and height were measured at baseline to 
calculate BMI.  BMI is a widely-utilized measurement of the proportion of adiposity to 
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muscle mass in the body, which is calculated by dividing the mass in kilograms by height 
in meters squared (kg/m2) (Fenn et al., 2015).  Each participant’s BMI value was 
categorized according to CDC criteria as underweight (BMI <18.5), normal weight (BMI 
18.5 to <25), overweight (BMI 25.0 to <30) or obese (BMI >30.0) (CDC, 2017).  
Food Security Survey.  The US Adult Food Security Survey (FSS) is a 10-item 
measure of past-year food security, which is defined as the availability and accessibility 
to nutritionally adequate foods and food insecurity is a socioeconomic condition resulting 
in uncertainty and lack of availability of nutritionally adequate food (Economic Research 
Service, USDA, 2012).  Response options are generally based on the self-reported 
endorsement of a variety of experiences and behaviors related to low food availability for 
a possible score range of 0-10.  Individuals’ food security categories are determined from 
this score and consist of high (score: 0), marginal (score: 1-2), low (score: 3-5) and very 
low (score: 6-10) food security.  Participants in the first two categories are considered to 
be relatively food secure and those in the two latter categories as food insecure.  
Eating Behavior Rating Questionnaire.  The Eating Behavior Rating 
Questionnaire (EBRQ) measures individuals’ self-reported frequency of healthy and 
unhealthy eating habits (e.g., eating regular meals, maintaining a healthy diet and weight) 
and preferences for consuming healthy (e.g., salad, meat) and unhealthy (e.g., candy, 
pizza) food options.  The EBRQ consists of 12 items and has been validated in samples 
with OUD (Nolan & Scagnelli, 2007; Peles et al., 2016).  Responses are indicated on a 5-
point Likert scale and total eating habit scores are calculated by summing ratings for the 
12 items, for a possible range in scores from 12 (not healthy habits) to 60 (very healthy 
habits).  In addition, the EBRQ includes a final item, “do you feel like eating now?”  
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Participants endorsing this item then complete nine additional ratings measuring their 
desire (0 (not at all) to 5 (extremely)) to eat a variety of specific foods and the amount (0 
(none at all) to 5 (as much as I can hold)) that they would eat of that food item.  
Food Frequency Questionnaire.  The National Health and Nutrition 
Examination Survey Food Frequency Questionnaire (CDC, 2017) examines individuals’ 
consumption of a comprehensive list of foods and beverages and has been widely used in 
population-level research to estimate nutrient intake.  Response options for its 139 items 
focus on the frequency with which the participant consumes each food item in the past 
year, ranging from never to daily.  As the primary focus of this project was on 
associations between opioids and sucrose response, we focused our analyses on the 24 
items of the FFQ assessing frequency of sweet foods and beverages.  
Nutrition Knowledge Questionnaire.  The Nutrition Knowledge Questionnaire 
(NKQ) has been used to characterize awareness of dietary standards and nutrient sources 
in individuals with OUD and is of particular interest because it has been shown to be 
associated with BMI in individuals receiving OAT (Moynihan et al., 2007; Peles et al., 
2016).  The NKQ includes 15 items with a total score range from 0 to 47 (Moynihan et 
al., 2007; Peles et al., 2016).  This measure consists of 4 subscales, including: dietary 
recommendations (score range: 0-17); nutrient sources (score range: 0-16); healthiest 
meal option (score range: 0-4); and association between diet and disease (score range: 0-
10).  
Power of Food Scales.  The Power of Food Scales (PFS) is a widely-established 
measure that examines the thoughts, motivations, and perceptions related to appetite in an 
environment in which palatable foods are readily available and has utility for predicting 
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individuals who experience elevated craving and overconsumption of palatable foods 
(Lowe et al., 2009).  Across 21 items, participants are asked to select how much they 
agree that the items describe them on a scale of 1 (don’t agree at all) to 5 (strongly agree).  
A total score is calculated by summing ratings across the items, with scores ranging from 
21 to 105.  
Yale Food Addiction Scale.  The Yale Food Addiction Scale (YFAS) is a 
widely-used measure in both clinical and non-clinical samples to identify individuals that 
show markers of substance dependence with the consumption of foods high in fat and/or 
sugar and thus risk for overweight and obesity (Gearhardt, Corbin, & Brownell, 2009; 
Pursey, Stanwell, Gearhardt, Collins, & Burrows, 2014) including among those receiving 
OAT for OUD (Sason, Adelson, Herzman-Harari, & Peles, 2018).  The YFAS consists of 
26 items assessing eating habits in the past year, with response options and resulting 8 
criteria generally resembling DSM-IV symptoms for substance dependence (Gearhardt et 
al., 2009).  It been widely used with adults but was of interest to us given the recently-
published study demonstrating an association between food addiction and 
overweight/obesity among patients receiving methadone for OUD treatment (Sason et al., 
2018).   
Pre-Session Measures 
 Upon arrival to each experimental session, participants completed a brief 
questionnaire assessing the number of hours they slept the previous night and the 
duration of time since their last food, caffeine, beverage, tobacco, and marijuana intake.  
For the OUD+ group, research staff also recorded the exact time when they last took their 
methadone or buprenorphine dose.  Finally, participants completed the six subjective 
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state VAS items described previously evaluating current levels of happiness, sadness, 
anxiety, sickness, nausea, and hunger.  
2.4 Experimental Sessions 
The study consisted of two outpatient laboratory sessions, both taking place on 
the same day and approximately three hours apart.  Participants were instructed to refrain 
from consuming any alcohol 12 hours prior to Session 1 and to refrain from all food, 
caffeine, tobacco, marijuana or beverages (except water) at least one hour prior to each 
experimental session.  They provided a urine specimen upon arrival to Session 1 and a 
breath sample prior to each session, with any instances of recent alcohol use prompting a 
rescheduling of that session.  At the beginning of Session 1, participants also completed a 
Timeline Followback of past day consumption of food and beverages, tobacco, caffeine, 
marijuana, and prescribed and over-the counter drugs, and this was updated at Session 2 
to reflect anything consumed between experimental sessions.  Finally, at the beginning of 
each session participants completed six visual analog scales (VAS) assessing baseline 
mood and subjective states (i.e., happiness, sadness, anxiety, sickness, nausea, hunger).   
Sucrose Taste Test 
All sucrose solutions were prepared by the University of Vermont Medical 
Center’s General Clinical Research Center from 50g medical grade sucrose powder 
(QuinTron, Milwaukee, WI) in distilled water at room temperature.  Prepared solutions 
were then transferred to 2-ounce amber glass bottles and stored in a refrigerator at 37-40 
degrees Fahrenheit, with the internal and external refrigerator temperatures monitored via 
a digital monitor.  Prepared solutions were stable for 60 days in refrigerated storage, after 
which, they were discarded.  The solutions were labeled with letters (A-F), with each 
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letter corresponding to a single sucrose concentration.  The solutions were administered 
at room temperature during the experimental sessions.  
Session 1.  During the first experimental session, participants completed the pre-
session activities described above and a research staff member oriented them to the 
experimental procedures while supplies (e.g., pipette, cotton swabs, solutions) were laid 
out next to them.  Participants rinsed their mouth out with water and then sampled six 
sucrose solutions (0, 0.1, 0.25, 0.5, 0.75, and 1.0M) three times each under double-blind 
conditions and in counterbalanced order (Figure 1).  Each solution was applied to the tip 
of the tongue by research staff using a cotton bud, consistent with procedures used in 
prior studies (e.g., Green et al., 2013).  Participants then rated the solution’s pleasantness 
and intensity using a 100mm VAS.  The solution pleasantness scale (“How much do you 
like this sample?”) ranged from 0 (dislike strongly) to 100 (like very much), with an 
anchor at 50 (neutral: neither like nor dislike) and four additional anchors placed at 
different segments on the scale (dislike moderately, dislike slightly and like slightly, like 
moderately).  The solution intensity scale (“How sweet is this sample?”) ranged from 0 
(not at all) to 100 (extremely).  Following completion of the VAS items, participants 
rinsed their mouth with spring water before continuing onto the next solution.  The inter-
trial interval between each sample was approximately 30 seconds in duration and the 
overall session duration was approximately 30 minutes.  For participants in the OUD+ 
group, this initial session took place immediately prior to ingestion of their daily 
methadone or buprenorphine dose; for the OUD- group, this session took place in the 
morning or early afternoon.  At the end of Session 1, the time of Session 2 was confirmed 
and participants were reminded not to consume any cannabis, tobacco, food or beverages 
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(except water) at least one hour prior to the next session.  OUD+ participants were asked 
to take their usual methadone or buprenorphine dose as prescribed immediately following 
the session and to record the time that they took their dose.  Participants received $50 for 
completing Session 1. 
Session 2.  The second experimental session took place approximately three hours 
following completion of Session 1.  Before completing the sucrose taste test, participants 
completed the pre-session measures described above, and the TLFB was updated to 
reflect any foods, beverages, cannabis, tobacco, and prescribed and over-the-counter 
medications consumed between the experimental sessions.  During Session 2, participants 
again sampled the six sucrose solutions three times each under double-blind 
counterbalanced conditions and rate each solution’s pleasantness and intensity following 
sampling, as described above for Session 1.  Participants were compensated $50 for 
completing this second session.  
2.5 Data analyses 
The primary aim in this study was to compare sucrose subjective response 
(pleasantness and intensity) across the 6 sucrose concentrations (0, 0.1, 0.25, 0.5, 0.75, 
and 1.0M) among adults receiving OAT for OUD (OUD+) and a comparison sample of 
adults without opioid or other drug use disorders (OUD-).  Mixed model repeated 
measures analyses (SAS, PROC MIXED) were used to compare groups and sessions 
(Pre-Post dosing) on the primary outcome measure defined as area under the sucrose dose 
curve (AUC) for subjective ratings of pleasantness and intensity.  We also used mixed 
model repeated measures analyses to compare groups and sessions on delta area under 
the sucrose dose curve (DAUC), defined as the change in ratings of pleasantness and 
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intensity at each sucrose dose from placebo.  The model included one within-subject 
fixed factor, session and two across-subject fixed factors, group (OUD+ vs. OUD-) and 
order of solution presentation.  Subject, nested within group and order, was a random 
factor in the model.  Additional mixed model analyses of variance were used to compare 
OUD+ vs. OUD- groups on mean pleasantness and intensity ratings at each 
concentration.  Fisher’s LSD was used to perform pairwise comparisons both between 
and within groups.   
Additionally, multivariate analyses were conducted to examine predictors of 
sucrose subjective response using stepwise linear regression.  Entry criteria for inclusion 
in the model was set at α=.05.  The dependent variables for these analyses were AUC for 
ratings of sucrose pleasantness and intensity.  Candidate predictor variables were selected 
based on the empirical literature.  Age, gender, alcohol use, cigarette smoking, cannabis 
use, pre-session mood ratings use, BMI, food insecurity, and OAT medication type were 
considered as potential predictors as there was evidence from the literature that these may 
be associated with sucrose subjective response and eating behaviors (Cornier et al., 2015; 
Darmon & Drewnowski, 2008; Ettinger, Duizer, & Caldwell, 2012; Hardikar, 
Höchenberger, Villringer, & Ohla, 2017; Krahn et al., 2006; Pomerleau, Garcia, 
Drewnowski, & Pomerleau, 1991).  
Finally, to examine several additional baseline characteristics which may 
influence eating behavior and weight gain among patients receiving OAT, our secondary 
outcome measures included: BMI, food security, eating behaviors, diet, and nutrition 
knowledge.  T-tests were used to compare groups on measures of body composition and 
eating measures (BMI) and continuous demographic variables.  T-tests were also used to 
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compare nutrition knowledge scores between groups and to compare groups on other 
continuous secondary outcome measures (total scores and subscores on FSS, EBR, PFS, 
etc.).  Chi square tests were used for group comparisons on categorical outcome measures 
(% meeting criterion on FSS and YFAS prevalence and FSS subcategories).  All analyses 
were performed using SAS statistical software Version 9.4 (SAS Institute, Cary, NC).  
2.6 Sample size justification  
 
Sample size estimates were based on detecting differences between OUD+ and 
OUD- participants on our primary outcome measure, which corresponds to a difference 
in the dose effect curve for ratings of pleasantness and intensity across sucrose 
concentrations.  The sample size of 40 participants/group was estimated to provide 
sufficient power (80%) using α=.05 to detect an ES=0.65 (Cohen’s d) between the two 
groups on ratings of pleasantness and intensity.  This magnitude of difference is similar 
to that observed by Green and colleagues (Green et al., 2013; d=0.72 for pleasantness and 
smaller than that observed for intensity, ES=1.40).  For secondary outcome measures, 
this effect size of d=0.65 corresponds to a 4.3-unit (10%) decrease in EBR score, a 1.74 
increase in FFS sum, and a 4.5-unit difference in BMI.  For dichotomous outcomes such 
as prevalence on the FSS or meeting criteria on YFAS or FSS subcategories, power was 
estimated to be greater than 80% to detect an approximate 30% difference. 
3. Results 
 
3.1 Participant characteristics 
 
 Participant characteristics are presented in Table 2.  OUD+ participants were 
significantly older and had completed fewer years of education than OUD- participants 
(p’s<0.01).  Fewer OUD+ participants reported being employed full-time, and the OUD+ 
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group reported lower household income than the OUD- group (p's<0.001).  With regard 
to baseline drug use, a greater percentage of OUD+ participants reported past-month 
tobacco and cannabis use relative to the OUD- group, while fewer OUD+ participants 
reported past-month alcohol use (p's<0.001). 
3.2 Session characteristics 
 
 As there were no significant differences between Sessions 1 and 2 for either 
group, data have been collapsed across the two sessions.  With regard to the ratings 
collected at the beginning of each visit, with OUD+ participants reporting higher ratings 
of Anxious, Sad and Nauseous and lower ratings of Happy relative to OUD- participants 
(p’s<0.01; Table 3).  The duration of time since last eating was greater for OUD+ than 
OUD- and, of those who smoked, OUD+ participants reported a shorter interval since last 
cigarette than OUD- participants (p’s<0.01).  Sessions averaged 9 minutes in duration 
and were longer for the OUD+ than OUD- group (9.5 ± 3.0 vs. 8.5 ± 1.4, respectively; 
p<0.01).  Finally, OUD+ participants completed Session 1 approximately 24 hours after 
taking their prior day’s opioid medication dose and completed Session 2 approximately 3 
hours after that day’s dose (not shown).   
3.3 Subjective sucrose response    
 On the primary outcome of subjective sucrose response, there was a significant 
group effect in ratings of pleasantness (“How much do you like this sample?”), with the 
OUD+ group reporting less overall sucrose liking than the OUD- group (AUC: 49.6 ± 1.3 
vs. 57.5 ± 1.3, p<0.001) (Figure 2, upper panel).  When pleasantness ratings were 
compared between groups at each sucrose concentration, OUD+ participants’ ratings of 
liking were significantly lower than OUD- participants at the placebo (0M) dose and 
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lowest sucrose concentrations (0.10M, and 0.25M, p’s<0.001) (Table 4).  In contrast, 
there was no difference between OUD+ and OUD- groups on ratings of intensity (“How 
sweet is this sample?”) (AUC: 36.4 ± 2.0 vs. 39.1 ± 2.0, respectively, p=0.35) (Figure 2, 
lower panel).  Ratings of sucrose intensity for both groups increased in a dose-dependent 
manner across sucrose concentrations (Table 4). 
Considering the pronounced differences between groups in subjective 
pleasantness response to placebo as noted above, we also examined participants’ sucrose 
response as change from their placebo rating (i.e., subjective response to the 0M 
solution).  Using this approach, there was a significant group effect, with a higher 
magnitude of change in pleasantness ratings from 0M in OUD+ vs. OUD- participants 
(AUCD: 20.7 ± 1.9 vs. 12.6 ± 1.9, p<0.01) (Figure 3, upper panel) and a lower magnitude 
of change in intensity ratings in OUD+ vs. OUD- (AUCD: 29.1 ± 1.9 vs. 35.6 ± 1.9, 
p=0.02) (Figure 3, lower panel).   
 In multivariate analyses, group (OUD+, OUD-) was the only significant predictor 
of subjective ratings of sucrose pleasantness (p=0.002), but did not predict sucrose 
intensity (p=0.95); age, gender, alcohol use, cigarette smoking, cannabis use, and pre-
session mood ratings were not associated with either subjective sucrose response 
(p’s>0.05).  Within the OUD+ group, there were no significant group differences 
between those receiving methadone vs. buprenorphine in sucrose pleasantness (AUC: 
36.4 ± 2.0 vs. 39.1 ± 2.0, p=0.35, not shown) or intensity (AUC: 36.4 ± 2.0 vs. 39.1 ± 
2.0, p=0.35, not shown).  Finally, sucrose response did not vary as a function of food 
insecurity status or BMI (p’s>0.05).   
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3.4 Baseline nutrition and eating behavior  
As noted previously, we sought to examine additional baseline characteristics 
associated with eating behaviors that may differ among patients with and without OUD.  
With regard to BMI, there was a significant group effect on percentage of participants in 
normal, overweight, and obese BMI categories (p=0.04) (Figure 4).  A smaller percentage 
of OUD+ participants had a BMI in the normal weight category relative to OUD- 
participants (23% vs. 43%, respectively; p=0.06), while a greater percentage presented 
with a BMI value in the obese range (45% vs. 20%, p=0.02).  With respect to food 
availability, prevalence of past-year food insecurity was significantly greater among 
OUD+ vs. OUD- participants (50%. vs. 10%, p<0.001) (Figure 5).  Group differences 
were also seen in the distribution of participants across the four food security categories 
(p<0.001), with fewer OUD+ participants reporting high food security relative to OUD- 
participants (p<0.001) and significantly more reporting very low security (p<0.001).   
In terms of eating behaviors, OUD+ participants presented with lower total scores 
on the Eating Behavior Rating Questionnaire relative to OUD- participants (35.2 ± 6.1 vs. 
43.4 ± 4.8, respectively; p<0.001).  The OUD+ group consistently reported a lower 
frequency of healthy individual habits (p’s<0.01) (Figure 6, top panel, left side) and a 
higher frequency of unhealthy habits (p’s<0.01) (top panel, right side).  Among the 
subsets of participants that reported feeling like eating during the screening session (38% 
and 50% in the OUD+ and OUD- groups, respectively), OUD+ participants generally 
reported a significantly greater eagerness to consume unhealthy foods relative to OUD- 
participants (p’s<0.05) (middle panel).  They also reported a desire to consume larger 
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amounts of unhealthy foods and smaller amounts of healthy foods (p’s<0.05) (lower 
panel). 
Similar outcomes were seen on the Food Frequency Questionnaire.  Of the 23 
sweet foods and beverages examined, the OUD+ group reported greater frequency of 
consumption than OUD- participants on 17 items, including greater daily consumption of 
6 sweetened food and beverages. (p’s<0.05) (Table 5).  The Timeline Followback also 
indicated that OUD+ participants consumed significantly greater amounts of sweetened 
caffeinated beverages relative to OUD- (p’s<0.01), translating to 89g vs. 4g of sugar from 
this source per day for OUD+ vs. OUD- participants, respectively (p<0.001) (Figure 7, 
upper panel).  In the OUD+ group, the largest source of added sugar was soda, 
accounting for 64% of the total average added sugar from caffeinated beverages (lower 
panel).   
Regarding participants’ knowledge and awareness of nutritional information, total 
scores on the Nutrition Knowledge Questionnaire were significantly lower in the OUD+ 
group, with OUD+ vs. OUD- participants answering 46% vs. 65% of items correctly 
(p<0.001) (Table 6).  The OUD+ group had significantly lower scores across all four 
subscales (p’s<0.001), with particular knowledge deficits related to associations between 
diet and disease.  
 Finally, with respect to food-related reinforcement, there were no significant 
differences between OUD+ and OUD- participants’ scores on the Power of Food Scale 
(46.1+20.3 and 46.8+15.6, respectively (p=0.86, not shown), which seeks to measure 
thoughts and perceptions related to appetite for palatable foods.  However, the percentage 
of participants endorsing Yale Food Addiction Scale criteria was numerically higher 
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among OUD+ participants for all eight criteria and significantly greater on two criteria 
(Table 7).  A similar pattern was seen on the portion of the Yale Food Addiction 
questionnaire assessing problems with overconsuming and/or craving palatable foods 
high in sugar and/or fat (Figure 8), wherein the percentages of OUD+ participants 
endorsing problems with individual foods were numerically greater on almost all items 
and significantly greater on two foods: soda (35% vs. 8%, p<0.01) and cheeseburgers 
(25% vs. 8%, p=0.03).  
4. Discussion 
 
 Data from preclinical and clinical research have suggested that opioid agonist 
medications may enhance subjective response to sweet flavors, and this may place 
opioid-dependent patients at risk for increased sugar consumption and subsequent weight 
gain and related problems.  In the present study, OUD+ participants exhibited a higher 
magnitude of change in pleasantness ratings from placebo compared to OUD- 
participants.  However, this effect was largely driven by pronounced group differences in 
participants’ perceived pleasantness of essentially unsweet solutions, with OUD+ 
participants rating the lowest concentration sucrose solutions as less pleasant than OUD- 
participants.  The only other study to evaluate a 0M sucrose concentration found no 
significant differences in pleasantness ratings between males receiving methadone 
maintenance treatment and a comparison sample without OUD (Bogucka-Bonikowska et 
al., 2002).  Our findings of no group differences at the higher sucrose concentrations are 
generally consistent with a prior study in which there were no differences in perceived 
sucrose pleasantness between males with and without OUD, including the highest 
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concentration examined (0.88M) (Bogucka-Bonikowska et al., 2002; but see Green et al., 
2013).   
On the measure of sucrose intensity, the findings were less clear.  On the overall 
AUC outcome measure, participants’ intensity ratings did not vary as a function of opioid 
status, with both groups showing similar dose-dependent increases.  However, OUD+ 
participants did exhibit a significantly lower magnitude of change in intensity ratings 
from placebo compared to OUD- participants.  Important to note, however, is that the 
magnitude of group differences in change from placebo was less robust for sucrose 
intensity than pleasantness.  These results are generally consistent with a prior study 
examining effects of methadone on subjective sucrose intensity, with no between-group 
differences observed on ratings of intensity at the highest sucrose concentration 
(Bogucka-Bonikowska et al., 2002).  However, the opioid-maintained participants in the 
prior study by Green and colleagues (2013) rated a 1.0M sucrose dose two-fold higher in 
sweet intensity compared to adults without OUD.  Methodological differences between 
studies in how sucrose pleasantness and intensity were measured may contribute to these 
differences.  For example, the present study and the prior report by Bogucka-Bonikowska 
and colleagues (2002) used an 100mm linear VAS for assessing sucrose subjective 
ratings, while Green and colleagues (2013) used a Generalized Labeled Magnitude Scale 
(170mm for pleasantness, 150mm for intensity) which uses a quasilogarithmic 
positive/negative scale and may be more sensitive to between-group differences 
(Bartoshuk et al., 2004). 
Taken together, the data from this and several prior studies suggest that the 
association between opioids and subjective sucrose response in humans may be less 
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robust than has been seen in the pre-clinical literature, which has consistently shown a 
large magnitude of effects of opioids on sweet preference of sweetened solutions and 
foods (e.g., Berridge, 1996; Castro & Berridge, 2017; Zhang & Kelley, 2002).  However, 
also important to note is that pre-clinical experiments have often utilized choice 
paradigms to evaluate sweet preference, which involve actual consumption of sweetened 
solutions or foods vs. water or normal chow.  Choice paradigms may assess more of the 
“wanting” process of reinforcement (i.e., approach toward a food reward or motivation to 
consume) rather than “liking” (i.e., palatability or pleasantness associated with a food), 
two possibly independent though not mutually exclusive constructs (Berridge, 1996).  
This may highlight the potentially complex mechanisms underlying our findings in this 
study in which opioid-dependent individuals look remarkably similar to comparison 
participants in terms of subjective ratings of sucrose pleasantness and intensity and yet 
consistently choose sugar and sweetened foods and beverages over healthier alternatives 
in their everyday lives (Alves et al., 2011; Gambera & Clarke, 1976; Nolan & Scagnelli, 
2007; Tomedi et al., 2012; Zador et al., 1996).  However, also critical to remember are 
the many other complex factors influencing eating and so many other health behaviors 
among opioid-dependent individuals (e.g., socioeconomic status, educational attainment, 
co-occurring conditions).   
We also sought to examine numerous additional baseline characteristics that may 
influence sucrose response and eating behavior more generally among patients receiving 
OAT, including BMI, food security, eating behaviors, diet, and nutrition knowledge. 
OUD+ participants presented with a higher mean BMI relative to comparison participants 
and nearly half were in the obese BMI category, which is consistent with prior studies on 
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this topic by our group and others (Baykara & Alban, 2019; Fenn et al., 2015; Nolan & 
Scagnelli, 2007; Sweeney et al., 2018).  Despite a high prevalence of obesity in the 
OUD+ group, half of the sample also experienced past-year food insecurity, with over a 
third endorsing the most severe level.  This is consistent with other studies in the general 
population demonstrating that lower food security is paradoxically associated with 
overeating and obesity (Dhurandhar, 2016; Kaiser et al., 2019; Rasmusson et al., 2019).  
It is also consistent with previous studies reporting severe food insecurity among 
individuals with OUD (Himmelgreen et al., 1998; McLinden et al., 2018; Strike, 
Rudzinski, Patterson, & Millson, 2012).  
OUD+ participants also presented with a markedly different profile of eating 
behaviors compared to those without OUD, including greater consumption of unhealthy 
foods as well as increased sugar craving and consumption (i.e., 89g sugar/day).  This is 
consistent with prior studies examining eating behaviors among individuals with OUD 
(Alves et al., 2011; Gambera & Clarke, 1976; Nolan & Scagnelli, 2007; Peles et al., 
2016; Tomedi et al., 2012; Zador et al., 1996).  This finding also generally aligns with the 
earlier observations of enhanced sensitivity to sucrose pleasantness among our OUD+ 
participants.  Peles and colleagues (2016) also reported that regular sweet food and 
beverage consumption was associated with a higher BMI in MMT patients.  OUD+ 
participants also had significantly lower nutrition knowledge relative to our comparison 
group as well as previously published knowledge scores among MMT patients in Israel 
(Peles et al., 2016; Sason et al., 2018).  Knowledge deficits in the areas of healthy eating 
may contribute to participants’ unhealthy eating behaviors and excessive sugar 
consumption, as gaps in nutrition knowledge have been associated with a higher BMI and 
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obesity in the general population (Moynihan et al., 2007; Valmórbida, Goulart, Busnello, 
& Pellanda, 2017) as well as among adults with OUD more specifically (Peles et al., 
2016).   
Finally, the OUD+ group reported having more problems with palatable foods 
high in sugar (i.e., overeating, craving, trouble controlling consumption, tolerance, 
interference of problem foods with psychosocial functioning).  These data are consistent 
with a recent study which examined loss-of-control (LOC) eating (i.e., perception that 
one cannot control what or amount that one is eating) among 447 methadone-maintained 
patients in the U.S. and found that a third endorsed LOC eating within the past 2 weeks 
(Goldschmidt et al., 2018).  Prevalence of recent LOC in that study was 3-fold higher 
than in previous studies among community samples of adults (Goldschmidt et al., 2018; 
Solmi, Hatch, Hotopf, Treasure, & Micali, 2014), and it was associated with greater 
depressive symptoms, past-month illicit drug use, pain severity, and self-perception of 
being overweight/obese.  Similarly, in another recent study of patients receiving MMT, 
10% met Yale criteria for food addiction and this was significantly associated with 
weight gain during treatment (Sason et al., 2018).  
Several methodological strengths of the present study are worth noting.  First, our 
sample of opioid-dependent participants was larger than those used in prior studies (e.g., 
N=14, Green et al., 2013; N=28, Bogucka-Bonikowska et al., 2002) and included similar 
numbers of methadone- and buprenorphine-maintained individuals.  Second, in an effort 
to evaluate subjective sucrose response with less confounding by opioid dose timing, 
participants in both groups completed the sweet taste test sessions twice, scheduled three 
hours apart (corresponding to approximate trough/peak medication levels for the OUD+ 
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group).  Third, we examined a larger range of sucrose concentrations than were evaluated 
in prior studies (e.g., 1 concentration, Green et al., 2013; 4 concentrations, Bogucka-
Bonikowska et al., 2002) and, unlike the study by Green and colleagues (2013), included 
a 0M sucrose dose to permit an evaluation of baseline placebo responding.  
Several limitations also merit mention.  First, the two groups differed on a range 
of baseline demographic and SES characteristics, including age, education, income, and 
employment status, all of which may be associated with prevalence of food insecurity, 
eating behaviors, diet, and BMI (Appelhans et al., 2012; Darmon & Drewnowski, 2008; 
de Mestral, Chatelan, Marques-Vidal, Stringhini, & Bochud, 2019; Kaiser et al., 2019).  
Thus, while these were not significant predictors of sucrose subjective response in our 
study sample, they may contribute to the large between-group differences we observed in 
prevalence of food insecurity and obesity as well as eating behaviors.  Second, the study 
was not sufficiently powered to detect differences in sucrose subjective response as a 
function of OAT medication type (i.e., methadone vs. buprenorphine).  While we were 
able to conduct a preliminary evaluation of this important question, future studies should 
more thoroughly investigate whether sucrose subjective response may vary as a function 
of OAT medication.  Finally, while we sought to examine as secondary outcomes the 
associations between sucrose subjective response and other participant characteristics, 
such as gender, BMI and food insecurity, our sample size for doing so was limited.   
Overall, these differences in eating behaviors and knowledge may place opioid-
dependent individuals at elevated risk for a host of serious health consequences.  There is 
a significant association between sugar-sweetened beverage consumption and increased 
incidence of mortality in the U.S. adults, with an 11% increase in all-cause mortality for 
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each additional 12 oz. serving/day of a sugar-sweetened beverage (Collin, Judd, Safford, 
Vaccarino, & Welsh, 2019).  Through this lens, the mean amounts of sugar consumed by 
our study sample in sugar-sweetened, caffeinated beverages alone translates to an 
approximate 30% increase in all-cause mortality.  Several studies have also found 
elevated blood glucose levels and increased incidence of diabetes mellitus among patients 
receiving methadone maintenance (Fareed, Byrd-Sellers, Vayalapalli, Drexler, & 
Phillips, 2013; Reece, 2013; Vallecillo et al., 2018).  Poor nutrition and unhealthy eating 
behaviors can also adversely impact OUD treatment outcomes such as treatment 
retention, illicit drug use and psychiatric symptoms (Goldschmidt et al., 2018; 
Richardson & Wiest, 2015).   
In summary, despite the well-established efficacy of OAT in reducing the 
significant health and societal consequences associated with OUD, patients receiving 
methadone or buprenorphine treatment may be at significant risk for obesity, diabetes, 
cardiovascular disease, stroke, and premature death (Fenn et al., 2015; Mysels & 
Sullivan, 2010; Schlienz et al., 2018).  While OUD+ participants in this study 
demonstrated generally similar subjective sucrose response, they presented with a 
markedly different profile of everyday eating behaviors and knowledge than individuals 
without SUDs.  Efforts to understand and improve nutritional knowledge and eating 
behaviors may improve health and opioid treatment outcomes in this vulnerable 
population (Jeynes & Gibson, 2017; Nabipour et al., 2014).  
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Table 1.  
 Published studies examining weight changes during opioid agonist treatment 
Reference Location N OAT Type  Outcomes 
Baykara & Alban  
(2019) Turkey 107 buprenorphine 
Significant increase in weight (8%) 
from T0 to T4mos 
Fenn et al.  
(2015) US 96 methadone 
Significant increases in weight 
(10%) and BMI (11%) from T0 to 
T2yrs 
Housova et al.  
(2005) 
Czech 
Republic 12 methadone 
Significant increase in BMI (1%) 
from T0 to T1yr 
Kabrt et al.  
(1999) 
Czech 
Republic 14 methadone 
Significant increases in weight 
(13%) and BMI (12%) from T0 to 
T1.5yrs 
Li et al.  
(2016) 
United 
Kingdom 20 
methadone, 
buprenorphine 
Significant increase in BMI (1%) 
from T0 to T1yr 
Montazerifar et 
al.  
(2012) 
Iran 55 methadone 
Significant increase in weight (6%) 
and BMI (7%) from T0 to T2mos 
Mysels et al. 
(2011) US 16 methadone 
2% and 4% increases in weight 
from T0 to T2mos and T6mos, 
respectively 
Okruhlica & 
Slezakova  
(2008) 
Slovakia 274 methadone 
Increase in % of participants in BMI 
categories from T0 to T1yr: 
overweight (15% to 29%) and 
obese categories (3% to 8%) 
Okruhlica & 
Slezakova  
(2012) 
Slovakia 42 methadone 
Significant increases in weight 
(12% & 15%) and BMI (11% & 
14%) from T0 to T1yr and to T4yrs, 
respectively 
Parvaresh et al.  
(2015) Iran 200 methadone 
Significant increase in weight (3%) 
from T0 to T6mos 
Peles et al.  
(2016) Israel 114 methadone 
Significant increase in BMI (8%) 
from T0 to T1yr 
Reimer et al. 
(2011) Germany 1015 methadone 
Significant increase in BMI (5%) 
from T0 to T1yr 
Sweeney et al.  
(2019) US 74 methadone 
Significant increase in % of 
participants in overweight, obese, or 
morbidly obese BMI categories 
from T0 (42%) to T1yr (76%), T2yrs 
(82%), and T3yrs (88%) 
Subscripts below timepoint (T) represent the duration of the interval reflected in the % of 
weight and/or BMI change, with T0 representing the baseline timepoint.  
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Table 2.  
Participant characteristics 
  
OUD+ 
(n=40) 
OUD- 
(n=40) p-value 
Age, yrs 36.8 ± 10.0 30.6 ± 8.7 0.004 
Male, % 53 50 0.823 
Race, Caucasian Non-Hispanic, % 93 88 0.456 
Education, yrs 12.7 ± 1.5 14.9 ± 1.7 <0.001 
Employed full-time, % 23 75 <0.001 
Annual median household income [IQR] 15000 [5000,25000] 
35000 
[35000,75000] <0.001 
Alcohol consumption, % (N) 28 (11) 65 (26) <0.001 
# of days/past 30 11.3 ± 12.9 7.1 ± 7.7 0.23 
# drinks per day  1.1 ± 1.4 0.54 ± 0.68 0.12 
Tobacco use, % (N) 83 (33) 13 (5) <0.001 
# of days/past 30 28.8 ± 5.0 20.4 ± 13.1 0.01 
# CPD 11.3 ± 6.3 4.1 ± 4.1 0.02 
Caffeine use, % (N) 98 (39) 98 (39) 1.00 
# of days/past 30 26.8 ± 8.2 23.4 ± 9.7 0.09 
Amount (mg) 315.1 ± 194.7 201.8 ± 169.7 0.01 
Cannabis use, % (N) 58 (23) 13 (5) <0.001 
OAT type    
Methadone, % 53   
Methadone dose (mg) 97.4 ± 33.6   
Buprenorphine, % 47   
Buprenorphine dose (mg) 12.8 ± 6.0   
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Table 3.  
 Experimental session characteristics 
Mean and standard deviation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 OUD+  
(n=40) 
OUD- 
(n=40) p-value 
Pre-session ratings (0-100)    
Happy 69.7 ± 22.6 
 
78.9 ± 12.0 
 
<0.01 
Anxious  26.5 ± 25.0 
 
13.4 ± 16.8 
 
<0.001 
Sad 11.7 ± 18.6 
 
5.0 ± 10.2 
 
<0.01 
Sick 5.9 ± 13.2 
 
3.6 ± 6.9 
 
0.17 
Nauseous  6.7 ± 13.3 
 
1.6 ± 4.1 
 
<0.001 
Hungry 35.5 ± 28.8 
 
33.2 ± 27.9 
 
0.60 
Session characteristics    
Mean session duration (min) 9.5 ± 3.0 8.5 ± 1.4 <0.01 
Duration between Sessions 1 and 2 (min) 200.5 ± 22.4 191.1 ± 10.4 0.02 
Time since last ate (min) 622.0 ± 361.1 368.2 ± 321.1 <0.001 
 
Time since last cigarette (min) 
(n=33) 
393.0 ± 642.4 
(n=5) 
1439.6 ± 1980.4 
 
<0.01 
 
Time since last cannabis use (min) 
(n=27) 
4086.3 ± 7412.0 
(n=9) 
4431.9 ± 7567.5 
 
0.87 
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Mean and standard deviation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. 
Sucrose subjective response ratings 
  
 OUD+ (N=40) 
OUD- 
(N=40) 
AUC    
Pleasantness  49.6 ± 1.3 57.5 ± 1.3 
Intensity 36.4 ± 2.0 39.1 ± 2.0 
Concentration dose (0M)   
Pleasantness  28.9 ± 19.4 45.0 ± 12.4 
Intensity 7.4 ± 8.0 3.5 ± 5.1 
Concentration dose (.10M)   
Pleasantness 31.9 ± 17.3 46.6 ± 11.5 
Intensity 11.1 ± 8.8 9.5 ± 11.5 
Concentration dose (.25M)   
Pleasantness  41.4 ± 14.4 53.7 ± 9.7 
Intensity 22.7 ± 14.2 25.5 ± 16.8 
Concentration dose (.50M)   
Pleasantness  53.7 ± 14.9 58.9 ± 10.1 
Intensity 41.2 ± 21.2 45.8 ± 21.8 
Concentration dose (.75M)   
Pleasantness  59.5 ± 18.2 64.3 ± 12.1 
Intensity 52.2 ± 22.6 55.5 ± 22.5 
Concentration dose (1.0M)   
Pleasantness  61.1 ± 17.2 63.4 ± 13.5 
Intensity 54.2 ± 23.6 58.2 ± 22.7 
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Table 5. 
Food Frequency Questionnaire: Sweet food and beverage items  
Food items  OUD+  (n=40) 
OUD- 
(n=40) p-value 
Beverages    
Tomato or vegetable juice 
>1 in past year 
>1 weekly 
>1 daily 
 
30 
10 
0 
 
33 
8 
3 
 
0.81 
0.69 
0.31 
Orange juice and grapefruit juice 
>1 in past year 
>1 weekly 
>1 daily 
 
75 
35 
5 
 
85 
18 
0 
 
0.26 
0.08 
0.15 
Apple juice 
>1 in past year 
>1 weekly 
>1 daily 
 
70 
45 
0 
 
63 
8 
0 
 
0.48 
<0.001 
1.0 
Grape juice 
>1 in past year 
>1 weekly 
>1 daily 
 
60 
18 
0 
 
28 
0 
0 
 
<0.01 
<0.01 
1.0 
Other 100% fruit juice or 100% fruit juice 
mixtures (e.g., pineapple, prune) 
>1 in past year 
>1 weekly 
>1 daily 
 
 
73 
38 
5 
 
 
78 
5 
0 
 
 
0.61 
<0.001 
0.15 
Other fruit drinks (e.g., cranberry cocktail, HI-C, 
lemonade, Kool-Aid) 
>1 in past year 
>1 weekly 
>1 daily 
 
 
75 
48 
13 
 
 
48 
8 
0 
 
 
0.01 
<0.001 
0.02 
Meal replacement, energy,  
or high-protein beverages 
>1 in past year 
>1 weekly 
>1 daily 
 
 
33 
18 
3 
 
 
30 
15 
10 
 
 
0.81 
0.76 
0.17 
Soft drinks, soda, or pop 
>1 in past year 
>1 weekly 
>1 daily 
 
85 
55 
38 
 
68 
20 
0 
 
0.07 
<0.01 
<0.001 
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Desserts   
Frozen yogurt, sorbet, or ices 
>1 in past year 
>1 weekly 
>1 daily 
 
40 
5 
0 
 
70 
5 
0 
 
<0.01 
1.0 
1.0 
Ice cream, ice cream bars, or sherbet 
>1 in past year 
>1 weekly 
>1 daily 
 
88 
43 
10 
 
98 
25 
0 
 
0.09 
0.10 
0.04 
Pudding or custard 
>1 in past year 
>1 weekly 
>1 daily 
 
68 
48 
3 
 
35 
18 
0 
 
<0.01 
<0.01 
0.31 
Cake 
>1 in past year 
>1 weekly 
>1 daily 
 
73 
20 
3 
 
95 
0 
0 
 
<0.01 
<0.01 
0.31 
Cookies or brownies 
>1 in past year 
>1 weekly 
>1 daily 
 
88 
10 
3 
 
100 
0 
0 
 
0.02 
0.04 
0.31 
Doughnuts, sweet rolls, Danish, or pop-tarts 
>1 in past year 
>1 weekly 
>1 daily 
 
80 
48 
5 
 
88 
18 
0 
 
0.36 
<0.01 
0.15 
Sweet muffins or dessert breads 
>1 in past year 
>1 weekly 
>1 daily 
 
63 
23 
0 
 
85 
13 
0 
 
0.02 
0.24 
1.0 
Fruit crisp, cobbler, or strudel 
>1 in past year 
>1 weekly 
>1 daily 
 
50 
15 
0 
 
63 
0 
0 
 
0.26 
0.01 
1.0 
Pie 
>1 in past year 
>1 weekly 
>1 daily 
 
70 
10 
0 
 
93 
0 
0 
 
<0.01 
<0.05 
1.0 
Chocolate candy 
>1 in past year 
>1 weekly 
>1 daily 
 
85 
55 
13 
 
98 
48 
8 
 
<0.05 
0.50 
0.46 
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Other candy 
>1 in past year 
>1 weekly 
>1 daily 
 
93 
65 
18 
 
88 
25 
0 
 
0.46 
<0.001 
<0.01 
Sugar/sweeteners added to foods and beverages    
Sugar or honey added to coffee or tea 
>1 in past year 
>1 weekly 
>1 daily 
 
63 
60 
48 
 
63 
33 
10 
 
1.0 
0.01 
<0.001 
Artificial sweetener added to coffee or tea 
>1 in past year 
>1 weekly 
>1 daily 
 
35 
25 
18 
 
8 
5 
5 
 
<0.01 
0.01 
0.08 
Sugar or honey added to foods  
>1 in past year 
>1 weekly 
>1 daily 
 
68 
55 
33 
 
60 
30 
10 
 
0.49 
0.02 
0.01 
Jam, jelly, or honey on breads or rolls 
>1 in past year 
>1 weekly 
>1 daily 
 
75 
35 
8 
 
75 
15 
3 
 
1.0 
0.04 
0.30 
% of participants endorsing consumption of items at frequency of at least once annually, 
weekly, and daily 
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Table 6. 
Nutrition Knowledge Questionnaire    
Knowledge areas assessed OUD+  (n=40) 
OUD- 
(n=40) p-value 
Total items correct, % 45 ± 19 64 ± 12 <0.001 
Dietary recommendations 52 ± 19 65 ± 12 <0.001 
Awareness of balance of good health food 
group proportions 42 ± 27 59 ± 21 <0.01 
Awareness of recommendations for 
consumption of fruit and vegetables 8 ± 27 23 ± 42 0.06 
Awareness to reduce saturated fat 53 ± 51 73 ± 45 0.07 
Awareness of which foods experts 
recommend eating less or more  61 ± 22 71 ± 12 0.01 
Nutrient sources  47 ± 27 67 ± 16 <0.001 
Knowledge of sources of oily fish 31 ± 35 38 ± 33 0.32 
Knowledge of sources of dietary fiber 51 ± 28 74 ± 17 <0.001 
Healthiest meal option  43 ± 31 64 ± 20 <0.001 
Sandwich 25 ± 44 25 ± 44 1.00 
High-fiber, low-fat meal 35 ± 48 50 ± 51 0.18 
Baked potato 60 ± 50 90 ± 30 <0.01 
Grilled meat 50 ± 51 93 ± 27 <0.001 
Association between diet and disease 29 ± 25 57 ± 23 <0.001 
Fiber 13 ± 33 65 ± 48 <0.001 
Fruits and vegetables 12 ± 28 30 ± 35 0.01 
Fat 44 ± 46 79 ± 34 <0.001 
Sugar 37 ± 26 58 ± 27 <0.001 
Salt 45 ± 50 85 ± 36 <0.001 
Mean and SD percent of total items correct 
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Table 7. 
Yale Food Addiction Scale criteria 
Criteria OUD+  (n=40) 
OUD- 
(n=40) p-value 
1. Substance taken in larger 
amount and for longer 
period than intended 
8% 0% 0.24 
 
2. Persistent desire or 
repeated unsuccessful 
attempts to quit 
 
93% 
 
83% 
 
0.18 
 
3. Much time/activity to 
obtain, use, recover 
 
23% 
 
13% 
 
0.24 
 
 
4. Important social, 
occupational, or 
recreational activities given 
up or reduced 
 
25% 
 
0% 
 
<0.01 
 
5. Use continues despite 
knowledge of adverse 
consequences 
 
20% 
 
13% 
 
0.36 
 
6. Tolerance 
 
38% 
 
10% 
 
<0.01 
 
7. Characteristic withdrawal 
symptoms 
 
15% 
 
3% 
 
0.12 
 
8. Use causes clinically 
significant impairment or 
distress 
 
10% 
 
3% 
 
0.62 
% of participants meeting each Yale Food Addiction Scale criterion  
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Figure Legends 
  
Figure 1.  Schematic illustrating experimental session procedures 
Figure 2.  Sucrose pleasantness (upper panel) and intensity (bottom panel) ratings 
between OUD+ (circles) and OUD- (squares) participants.  Error bars represent SEM and 
asterisks indicate significant between-group differences in ratings at each sucrose 
concentration.  Filled symbols indicate significant within-group differences in ratings at 
each concentration from placebo (0M), while unfilled indicates that ratings are not 
significantly different from placebo.  
Figure 3.  Change from placebo (0M sucrose concentration) in sucrose pleasantness 
(upper panel) and intensity (lower panel) ratings between OUD+ (circles) and OUD- 
(squares) participants.  Error bars represent SEM and asterisks indicate significant 
between-group differences in change in ratings from placebo at each sucrose 
concentration.  Filled symbols indicate significant within-group differences in change in 
ratings at each concentration from placebo (0M), while unfilled indicates that the change 
in ratings are not significant from placebo.  Y-axes are represented on a smaller scale to 
permit a more detailed inspection of data.   
Figure 4.  Percent of OUD+ vs. OUD- participants in normal, overweight, and obese 
BMI categories.  Asterisks indicate significant between-group differences. 
Figure 5.  Prevalence of past-year food insecurity between OUD+ vs. OUD- participants 
and percent of OUD+ and OUD- participants across the 4 USDA food security categories 
(high, marginal, low, and very low).  Asterisks indicate significant between-group 
differences.  
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Figure 6.  Mean frequency ratings on the 12 items of the Eating Behavior Ratings 
Questionnaire between OUD+ vs. OUD- participants (top panel) and mean ratings on the 
9 food items among OUD+ vs. OUD- participants that endorsed that they felt like 
consuming (middle and bottom panel).  The middle panel displays mean eagerness 
ratings and the bottom panel displays mean amount of consuming the food items.  Error 
bars represent SEM and asterisks indicate significant between-group differences.  
Figure 7.  Mean amount of added sugar from caffeinated beverages consumed per day 
(g/day) among OUD+ vs. OUD- participants.  An asterisk indicates significant between-
group differences.  
Figure 8.  Comparison in the percent of OUD+ vs. OUD- participants endorsing 
problems with foods on the Yale Food Addiction Scale.  The upper panel represents the 
percent of participants endorsing problems with the 7 high-sugar items and the bottom 
panel presents the percent of participants endorsing problems with the 7 high-fat items.  
Asterisks indicate significant between-group differences.  
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Figure 1. 
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Sucrose Taste Test 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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Figure 8. 
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